Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

A patient receives cancer treatment. Photo: John Moore/Getty Images

A new health technology startup called Driver wants to connect cancer patients and survivors to treatments, clinical trials and cancer centers across the country, with the hopes of being global.

Yes, but: This warrants skepticism. It's an expensive service, so initially it will cater to more affluent people. There are also questions about how the technology will operate within the U.S. insurance system and whether it would lead to overtreatment.

How it works: A patient downloads the Driver app and gives consent for the company to collect medical records and tumor tissue. The technology then finds cancer treatments or clinical trials that are available and hospitals they can go to, which can lead to a video conference with an oncologist about next steps and future appointments.

A "patient support team" will evaluate people's health insurance, and that may limit their options, Driver co-founder Petros Giannikopoulos said.

  • Driver's first product, called Hyperdrive, is targeted for cancer patients. It costs $3,000 upfront and then $20 per month as a subscription.
  • The second product, called Everdrive, is targeted for cancer survivors and other presumably healthy people. It costs $500 upfront with a $20-per-month subscription.

The bottom line: These costs are unaffordable for most middle- and lower-income people, especially those on Medicare and Medicaid. And they don't include travel costs if a patient wants to go to a recommended hospital for treatment β€” costs that Driver currently would not cover.

  • Giannikopoulos said they plan to cover the costs of the products for underserved communities initially from their own funding and then through corporate sponsors. He would not say how much venture capital Driver has raised.
  • He also hopes this will become an add-on health benefit for employers to offer. However, those costs inevitably would be absorbed by employees in the form of lower compensation.
  • It's unclear how palliative care fits into the technology.

The big picture: Giannikopoulos, whose company is partnering with the National Cancer Institute, said the "first and most important barrier is knowledge" when it comes to cancer care. But as more patients grapple with higher out-of-pocket costs, financial barriers are becoming a much bigger concern, and Driver doesn't really solve that.

  • Driver will help hospitals, though. It recruited more than two dozen wealthy hospitals with prominent cancer programs, such as Mayo Clinic and Massachusetts General Hospital, to be part of its network. The app will not only fill clinical trials, but it will also fill beds for hospitals that have seen stagnating revenue.

Go deeper

18 mins ago - Health

Moderna to file for FDA emergency use authorization for COVID-19 vaccine

Photo illustration by STR/NurPhoto via Getty Images

Moderna announced that it plans to file with the FDA Monday for an emergency use authorization for its coronavirus vaccine, which the company said has an efficacy rate of 94.1%.

Why it matters: Moderna will become the second company to file for a vaccine EUA after Pfizer did the same earlier this month, potentially paving the way for the U.S. to have two COVID-19 vaccines in distribution by the end of the year. The company said its vaccine has a 100% efficacy rate against severe COVID cases.

The social media addiction bubble

Illustration: Annelise Capossela/Axios

Right now, everyone from Senate leaders to the makers of Netflix's popular "Social Dilemma" is promoting the idea that Facebook is addictive.

Yes, but: Human beings have raised fears about the addictive nature of every new media technology since the 18th century brought us the novel, yet the species has always seemed to recover its balance once the initial infatuation wears off.

Young people's next big COVID test

Illustration: Eniola Odetunde/Axios

Young, healthy people will be at the back of the line for coronavirus vaccines, and they'll have to maintain their sense of urgency as they wait their turn β€” otherwise, vaccinations won't be as effective in bringing the pandemic to a close.

The big picture: "It’s great young people are anticipating the vaccine," said Jewel Mullen, associate dean for health equity at the University of Texas. But the prospect of that enthusiasm waning is "a cause for concern," she said.